Page 3 - மாற்றாந்தாய் டியாஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மாற்றாந்தாய் டியாஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மாற்றாந்தாய் டியாஸ் Today - Breaking & Trending Today

Viking Therapeutics (VKTX) Q1 2021 Earnings Call Transcript


Operator
Welcome to the Viking Therapeutics 2021 first-quarter financial results conference call. [Operator instructions] As a reminder, this conference call is being recorded today, April 28th, 2021. I would now like to turn the conference over to Viking s manager of investor relations, Stephanie Diaz. Please go ahead, Stephanie.
Stephanie Diaz
Manager of Investor Relations
Hello, and thank you all for participating in today s call. Joining me today is Brian Lian, Viking s president and CEO; and Greg Zante, Viking s CFO. Before we begin, I d like to caution that comments made during this conference call, today, April 28th, 2021, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking s expectations regarding its development activities, timelines, and milestones. ....

Andy Hsieh , Michael Morabito Chardan , Raymond James , Mayank Mamtani , Derek Archila , Steve Seedhouse , Andy Hsieh William Blair , Matthew Luchini , Stephanie Diaz , Jay Olson , Sahil Kazmi , Michael Morabito , Ryan Deschner , Greg Zante , Ryan Deschner Raymond James , Scott Henry , Sahil Kazmib Riley , William Blair , Exchange Commission , Jay Olson Oppenheimer Co , International Liver Congress , Viking Therapeutics , Viking Therapeutic , Brian Lian , Securities Litigation Reform Act , Chief Executive ,

Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes


Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
March 10, 2021 00:20 ET
| Source:
Avid Bioservices, Inc
Avid Bioservices, Inc
Tustin, California, UNITED STATES
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Avid SPV, LLC (the “Issuer”), has priced its sale of $125 million aggregate principal amount of exchangeable senior notes due 2026 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuan ....

United States , Exchange Commission , Avid Bioservices Inc , Aboutavid Bioservices Inc , Securities Act , Seriese Convertible Preferred Stock , Avid Bioservices , Private Securities Litigation Reform Act , Stephanie Diaz , Vida Strategic Partners , Nasdaq Cdmo , Contract Manufacturing , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , ஆர்வமுள்ள உயிர் சேவைகள் இன்க் , பத்திரங்கள் நாடகம் , ஆர்வமுள்ள உயிர் சேவைகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , மாற்றாந்தாய் டியாஸ் , விடா மூலோபாய கூட்டாளர்கள் , நாஸ்டாக் கதிமோ , ஒப்பந்த உற்பத்தி ,

Revolution Medicines to Participate in Upcoming Investor Conferences


Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021
Format: Virtual conference
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
The company s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RM ....

Tim Brons , Marka Goldsmith , Stephanie Diaz , Napa Valley Forum , Revolution Medicines Inc , Revolution Medicines , Annual Healthcare Conference , Annual Napa Valley , Annual Healthcare , For Investors , Vida Strategic Partners Stephanie Diaz , Vida Strategic Partners Tim Brons , மார்க்கா பொற்கொல்லர் , மாற்றாந்தாய் டியாஸ் , நாபா பள்ளத்தாக்கு மன்றம் , புரட்சி மருந்துகள் இன்க் , புரட்சி மருந்துகள் , ஆண்டு சுகாதாரம் மாநாடு , ஆண்டு நாபா பள்ளத்தாக்கு , ஆண்டு சுகாதாரம் , க்கு முதலீட்டாளர்கள் , விடா மூலோபாய கூட்டாளர்கள் மாற்றாந்தாய் டியாஸ் ,